Journal article

What is the best contemporary treatment for in-stent restenosis?

Peter Barlis, Mark CG Horrigan, Robert K Chan, Andrew E Ajani, George Proimos, Wendy Schumer, William J van Gaal, Michael Rowe, David Eccleston, Bryan BP Yan, Yu Mun Cheong, Les E Oliver, David J Clark

Cardiovasc Revasc Med | Published : 2005


In-stent restenosis (ISR) remains a challenging problem in percutaneous coronary intervention and the optimal treatment strategy remains unclear. The aim of this study was to compare the 18 month clinical outcomes in patients receiving sirolimus-eluting stents (SES) with vascular brachytherapy (VBT) for the treatment of ISR. Twenty-five consecutive patients treated with VBT were compared with 29 patients who had SES deployment for ISR. Major adverse cardiac events (MACE) were defined as a combination of death from cardiac causes, nonfatal myocardial infarction, or repeat TVR. At 18 month follow-up, the MACE rate was significantly lower in the SES compared with the VBT group (14% vs 40%, P=.0..

View full abstract